Curian Capital’s Esperion Therapeutics ESPR Stock Holding History

Curian Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,413	Closed	-$223K	–	594
2015 Q1	$223K	Buy	+2,413	New	+$156K	﹤0.01%	595

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Curian Capital's ESPR Position: Q2 2015 in Review

Curian Capital sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 2,413 shares — an estimated $223K sold.

Curian Capital first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $223K in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

Curian Capital reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
Curian Capital sold 2,413 Esperion Therapeutics shares in Q2 2015, an estimated $223K.
Curian Capital first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
Curian Capital's Esperion Therapeutics position peaked at $223K in Q1 2015.
151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Curian Capital's 13F filing for Q2 2015, filed 28 Jul 2015.